Crispina Calsada - May 20, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Financial Officer
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
May 20, 2024
Transactions value $
$0
Form type
4
Date filed
5/21/2024, 04:21 PM
Previous filing
Jan 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +462K $0.00 462K May 20, 2024 Common Stock 462K $2.01 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.